Skip to main content

MANGOCEUTICALS, INC.

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

MGRX$0.20+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

The following exhibits are filed herewith or incorporated by reference herein:

Filed/ · Incorporated by Reference
Exhibit · Description of · Furnished · Filing · File
Number · Exhibit · Herewith · Form · Exhibit · Date · Number
3.1Certificate of Designations, Preferences and Rights of 6% Series B Convertible Preferred Stock of Mango & Peaches Corp., filed with the Secretary of State of Texas on July 3, 20258-K3.17/9/2025001-41615
4.1Form of Common Stock Purchase Warrant – Unit Offering (May 2025)8-K4.15/29/2025001-41615
4.2Common Stock Purchase Warrant to purchase 275,482 shares of common stock, issued to Indigo Capital LP dated May 27, 20258-K4.25/29/2025001-41615
4.3#Common Stock Purchase Warrant to purchase 50,000 shares of common stock, issued to Tiger Cub Trust dated July 21, 20258-K4.17/22/2025001-41615
10.1Master Distribution Agreement dated March 24, 2025, between Navy Wharf, Ltd, as supplier, and Mangoceuticals, Inc., as distributor8-K10.13/25/2025001-41615
10.2Form of Securities Purchase Agreement dated April 11, 2025, relating to the sale of 100 shares of Series B Convertible Preferred Stock8-K10.14/17/2025001-41615
10.3Promissory Note dated April 15, 2025, evidencing $500,000 owed by Mangoceuticals, Inc. to Indigo Capital LP8-K10.24/17/2025001-41615
10.4+Intellectual Property Purchase Agreement dated April 24, 2025, by and between Mangoceuticals, Inc., as purchaser and Smokeless Technology Corp., as seller8-K10.14/25/2025001-41615
10.5+Consulting Agreement dated April 24, 2025, between Mangoceuticals, Inc. and Strategem Solutions, Inc.8-K10.24/25/2025001-41615
10.6#First Amendment to Amended and Restated Executive Employment Agreement dated April 24, 2025 and effective April 1, 2025, by and between Mangoceuticals, Inc. and Jacob Cohen8-K10.34/25/2025001-41615
10.7#Promissory Note dated May 2, 2025 in the principal amount of $100,000, between Mangoceuticals, Inc., borrower and The Tiger Cub Trust, lender8-K10.15/6/2025001-41615
10.8Master Distribution Agreement dated May 14, 2025, between PrevenTech Solutions, LLC, as distributor, and Mangoceuticals, Inc., as supplier10-Q10.235/15/2025001-41615
10.9Mutual Rescission and Release Agreement dated May 22, 2025 and effective May 22, 2025, by and between Mangoceuticals, Inc. and ArcStone Securities and Investments Corp.8-K10.15/23/2025001-41615
10.10Mutual Rescission and Release Agreement dated May 22, 2025 and effective May 22, 2025, by and between Mangoceuticals, Inc. and Smokeless Technology Corp.8-K10.25/23/2025001-41615
10.11Mutual Rescission and Release Agreement dated May 22 2025 and effective May 22, 2025, by and between Mangoceuticals, Inc. and Strategem Solutions Inc.8-K10.35/23/2025001-41615
10.12Form Common Stock Subscription Agreement – Unit Offering (May 2025)8-K10.15/29/2025001-41615
10.13Agreement to Amend Promissory Note dated May 27, 2025, by and between Mangoceuticals, Inc. and Indigo Capital LP8-K10.25/29/2025001-41615
10.14Amended and Restated Convertible Promissory Note dated May 27, 2025, by and between Mangoceuticals, Inc., as borrower, and Indigo Capital LP, as holder8-K10.35/29/2025001-41615
10.15#Agreement to Amend Promissory Note dated July 21, 2025, by and between Mangoceuticals, Inc. and to Tiger Cub Trust8-K10.27/22/2025001-41615
10.16#Amended and Restated Convertible Promissory Note dated July 21, 2025, by and between Mangoceuticals, Inc., as borrower, and to Tiger Cub Trust, as holder8-K10.37/22/2025001-41615
10.17Mutual Rescission and Release Agreement dated and effective July 30, 2025, by and between Mangoceuticals, Inc. and Navy Wharf, Ltd.8-K10.18/4/2025001-41615
31.1*Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley ActX
31.2*Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley ActX
32.1**Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley ActX
32.2**Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley ActX
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentX
101.SCH*XBRL Taxonomy Extension Schema DocumentX
101.CAL*XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEF*XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LAB*XBRL Taxonomy Extension Label Linkbase DocumentX
101.PRE*XBRL Taxonomy Extension Presentation Linkbase DocumentX
104*Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document SetX
  • Filed herewith.

** Furnished herewith.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.